- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02923817
Clinical Trial Using Bone Marrow-derived Mononuclear Cells for Spinal Cord Injury (DNH)
Phase I-II Clinical Trial Using Bone Marrow-derived Mononuclear Cells for Spinal Cord Injury
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Recruitment process:
The investigators selects the candidate of the study that fulfill the inclusion criteria and not violate any exclusion criteria from patients with spinal cord injury that admitted to the department of neurosurgery - Danang hospital. The investigators then ask the patients and patients family for informed consent. The patients that submit the informed consent to participate is recruited to the study.
Procedure description:
The patients is moved to operation theater at the day of the procedure. The bone marrow of the patients is harvested by two investigators. The mononuclear cells of the bone marrow is extracted from the bone marrow by using gravity centrifugation with Ficoll Paque 1.073. The mononuclear cells is transferred to 5 mL syringe and handed back to the investigator. The investigator will transplant the whole cell preparation back to the patients by lumbar injection.
A final supernatant layer of the preparation is also sent to the lab for microbiological and endotoxin testings. One small portion of the cell preparation is sent to the laboratory for cell count and cluster of distribution tests.
The patient is transferred back to the patient room and monitor for the outcomes at 2 weeks, 4 weeks, 2 months, 4 months, 6 months. All of the data is entered, stored and monitored via the eCB database system of TRI Cente, Kobe.
Data Analysis:
Primary Endpoint:
A list is prepared for each subject with the name of AE developed, its severity and seriousness, causal relationship with the treatment, and outcome. In addition, the incidence of AEs in all cases and the 95% confidence interval are estimated. For each AE type, the incidence, incidence by severity, and incidence by seriousness are calculated in addition to estimation of the rate of each AE and its 95% confidence interval in all cases.
Secondary Endpoint:
Regarding secondary endpoints, the Wilcoxon signed rank test is used to compare the baseline value at registration and value at 6 months after cell transplantation. In addition, assuming the scores in each secondary endpoint to be consecutive scores, a linear mixed model with time point as a fixed effect and cases as random effects is fitted to the data at registration and 2 and 6 months after cell transplantation after assuming an appropriate covariance structure between time points to assess their chronological changes.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ba Ngoc Nguyen, MD
- Phone Number: +84905238311
- Email: ba_neurosur@yahoo.com.vn
Study Contact Backup
- Name: Lam Huu Nguyen, MD
- Phone Number: +84916009802
- Email: nguyenhuulam@yahoo.com
Study Locations
-
-
-
Danang, Vietnam, 59000
- Recruiting
- Danang Hospital
-
Contact:
- Ba Ngoc Nguyen, MD
- Phone Number: +84905238311
- Email: ba_neurosur@yahoo.com.vn
-
Principal Investigator:
- Ba N Nguyen, MD
-
Sub-Investigator:
- Lam h Nguyen, MD
-
Sub-Investigator:
- Anh TN Pham, MD
-
Sub-Investigator:
- Bach N Nguyen, MD
-
Sub-Investigator:
- Tri H Le, MD
-
Sub-Investigator:
- Phong H Tong, BSc.
-
Sub-Investigator:
- Nam VK Le, BPharm.
-
Sub-Investigator:
- Thanh H Le, BSc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with spinal cord injuries classified as A-B on the ASIA impairment scale
- Patients injured 3 weeks to 1 year previously
- Patients with partial spinal cord injury demonstrated by diagnostic imaging
- Patients aged between 20 and 60 years at the acquisition of informed consent
- Patients who submitted written informed consent by themselves
Exclusion Criteria:
- Patients with a completely transected spinal cord
- Patients with central spinal cord injury
- Patients with organ failure with SOFA score of 3 points or higher
- Patients in whom hepatitis B, hepatitis C, human immunodeficiency virus infection, or leukemia infection cannot be denied
- Patients with malignant tumour or a history of malignant tumour within 5 years
Patients with following disease/disorder:
Myeloproliferative disorder or myelodysplastic syndrome Poorly controlled ischemic heart disease Autoimmune disease Spinal stenosis Limb paralysis due to central nervous system disorder not attributed to spinal cord injury Hepatic dysfunction Renal dysfunction Poorly controlled psychiatric disorder Complex multiple trauma
- Patients who are participating in other clinical trials or who completed participation within 6 months
- Patients who are pregnant or possibly pregnant
- Other patients who are judged to be ineligible by investigators
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety profile and adverse effects of the procedure
Time Frame: 6 months from the time when patients receive the treatment
|
Causal relationship, incidence, severity, and seriousness of all adverse events (AEs) experienced following cell transplantation up to the day of the final observation are assessed.
|
6 months from the time when patients receive the treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Motor function
Time Frame: At 2 weeks, 4 weeks, 2 months, 4 months, 6 months after the transplantation
|
Motor function score in the neurological classification of spinal cord injury: Amount of change from the time of registration to 6 months after cell transplantation
|
At 2 weeks, 4 weeks, 2 months, 4 months, 6 months after the transplantation
|
Sensory function
Time Frame: At 2 weeks, 4 weeks, 2 months, 4 months, 6 months after the transplantation
|
Sensory function score in the neurological classification of spinal cord injury (light touch sensation score + pinprick sensation score): Amount of change from the time of registration to 6 months after cell transplantation
|
At 2 weeks, 4 weeks, 2 months, 4 months, 6 months after the transplantation
|
ASIA Impairment Scale
Time Frame: At 2 weeks, 4 weeks, 2 months, 4 months, 6 months after the transplantation
|
Change on the ASIA impairment scale from the time of registration to 6 months after cell transplantation
|
At 2 weeks, 4 weeks, 2 months, 4 months, 6 months after the transplantation
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ba Ngoc Nguyen, MD, Danang Hospital
- Study Director: Yoshihisa Suzuki, MD, PhD., Kitano Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DNHSCI124HP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Cord Injuries
-
Khon Kaen UniversityUnknownInjuries, Spinal Cord
-
Universidade do Vale do ParaíbaCompletedInjuries, Spinal Cord
-
Ekso BionicsBurke Medical Research InstituteCompletedInjuries, Spinal CordUnited States
-
ReWalk Robotics, Inc.Unknown
-
InVivo TherapeuticsTerminated
-
Shepherd Center, Atlanta GACompletedInjuries, Spinal Cord
-
M.D. Anderson Cancer CenterActive, not recruitingMetastatic Epidural Spinal Cord CompressionUnited States
-
Wroclaw Medical UniversityInstitute of Immunology and Experimental Therapy of the Polish Academy of... and other collaboratorsUnknownComplete Spinal Cord InjuriesPoland
Clinical Trials on Transplantation of autologous bone marrow-derived mononuclear cells by lumbar injection
-
Timothy J Nelson, MD, PhDMayo ClinicCompletedCongenital Heart DiseaseUnited States
-
Xijing HospitalUnknownMyocardial InfarctionChina
-
Chinese PLA General HospitalUnknownLeft Ventricular Dysfunction | Chronic Myocardial Ischemia | Old Myocardial InfarctionChina
-
Shanghai Changzheng HospitalRecruitingSpinal Cord InjuryChina
-
Novo Cellular Medicine Institute LLPUnknownMultiple Sclerosis, Relapsing-RemittingIndia, Trinidad and Tobago
-
Vinmec Research Institute of Stem Cell and Gene...RecruitingSequelae of Injuries of HeadVietnam
-
Nantes University HospitalCompleted
-
IRCCS San RaffaeleSuspended
-
University Hospital, Clermont-FerrandCompletedIschemic Heart DiseaseFrance
-
TotipotentSC Scientific Product Pvt. Ltd.Thermogenesis Corp.CompletedCritical Limb IschemiaIndia